|
[1]BOSCH A, DUMORTIER J, MAUCORT-BOULCH D, et al.Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence[J].J Hepatol, 2015, 63 (6) :1449-1458.
|
|
[2]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensuson the diagnosis and management of primary biliary cirrhosis (cholangitis) (2015) [J].J Clin Hepatol, 2015, 31 (12) :1980-1988. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.原发性胆汁性肝硬化 (又名原发性胆汁性胆管炎) 诊断和治疗共识 (2015) [J].临床肝胆病杂志, 2015, 31 (12) :1980-1988.
|
|
[3]NEUSCHWANDER-TETRI BA.Targeting the FXR nuclear receptor to treat liver disease[J].Gastroenterology, 2015, 148 (4) :704-706.
|
|
[4]HIRSCHFIELD GM, MASON A, LUKETIC V, et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology, 2015, 148 (4) :751-761.e758.
|
|
[5]NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebocontrolled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.
|
|
[6]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.
|
|
[7]GRIGORIAN AY, MARDINI HE, CORPECHOT C, et al.Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis:a meta-analysis[J].Clin Res Hepatol Gastroenterol, 2015, 39 (3) :296-306.
|
|
[8]CHEUNG A, LAPOINTE-SHAW L, KOWGIER M, et al.Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes[J].Aliment Pharmacol Ther, 2016, 43 (2) :283-293.
|
|
[9]HOSONUMA K, SATO K, YAMAZAKI Y, et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol, 2015, 110 (3) :423-431.
|
|
[10] RAUTIAINEN H, KARKKAINEN P, KARVONEN AL, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology, 2005, 41 (4) :747-752.
|
|
[11]RABAHI N, CHRETIEN Y, GAOUAR F, et al.Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone[J].Gastroenterol Clin Biol, 2010, 34 (4-5) :283-287.
|
|
[12]RAUTIAINEN H, KARKKAINEN P, KARVONEN AL, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology, 2005, 41 (4) :747-752.
|
|
[13]TSUDA M, MORITOKI Y, LIAN ZX, et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology, 2012, 55 (2) :512-521.
|
|
[14]HIRSCHFIELD GM, GERSHWIN ME, STRAUSS R, et al.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid:a proof-of-concept study[J].Hepatology, 2016, 64 (1) :189-199.
|
|
[15]ZHOU M, LEARNED R, ROSSI S, et al.Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice[J].Hepatology, 2016, 63 (3) :914-929.
|
|
[16]HEGADE V, KENDRICK S, DOBBINS R, et al.Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis:a double-blind, randomised, placebo-controlled, crossover, phase 2a study[J].Lancet, 2017, 389 (10074) :1114-1123.
|
|
[17]Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis.Guidelines for the management of primary biliary cirrhosis:The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan[J].Hepatol Res, 2014, 44 (Suppl 1) :71-90.
|
|
[18]LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology, 2015, 149 (7) :1804-1812.e1804.
|
|
[19]CARBONE M, SHARP SJ, FLACK S, et al.The UK-PBC risk scores:derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J].Hepatology, 2016, 63 (3) :930-950.
|
|
[20]TRIVEDI PJ, BRUNS T, CHEUNG A, et al.Optimising risk stratification in primary biliary cirrhosis:AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response[J].J Hepatol, 2014, 60 (6) :1249-1258.
|
|
[21]European Association for the Study of the liver.EASL clinical practice guidelines:the diagnosis and management of patients with primary biliary cholangitis[J].J Hepatol, 2017, 67 (1) :145-172.
|
DownLoad: